Last $0.16 USD
Change Today -0.019 / -10.56%
Volume 40.5K
TNGN On Other Exchanges
As of 3:46 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

tengion inc (TNGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/13 - $1.04
52 Week Low
04/14/14 - $0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TENGION INC (TNGN)

Related News

No related news articles were found.

tengion inc (TNGN) Related Businessweek News

No Related Businessweek News Found

tengion inc (TNGN) Details

Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery. The company has a license agreement with Children’s Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology. Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina.

25 Employees
Last Reported Date: 04/9/14
Founded in 2003

tengion inc (TNGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $462.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $336.6K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $380.8K
Compensation as of Fiscal Year 2013.

tengion inc (TNGN) Key Developments

Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Tengion, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported loss from operations of $4,409,000 against $4,143,000 for the same period a year ago. Net loss was $34,258,000 or $1.91 per share basic and diluted against $5,774,000 or $2.11 loss per share basic and diluted for the same period a year ago. Adjusted net loss was $6,211,000 or $0.35 loss per share against $5,535,000 or $2.02 for the same period a year ago. The increase in research and development expense was primarily due to an increase in compensation and related expenses resulting from additional employees and an increased use of clinical and regulatory consultants, as well as an increase in external services related to the clinical trials for the Neo-Kidney Augment program. The increased adjusted net loss was primarily due to an increase in research and development expense of $0.3 million and an increase in interest expense of $0.5 million, offset in part by a decrease in general and administrative expense of $0.1 million.

Tengion, Inc., Annual General Meeting, May 02, 2014

Tengion, Inc., Annual General Meeting, May 02, 2014., at 12:30 US Eastern Standard Time. Location: Philadelphia Airport Marriott, One Arrivals Road. Agenda: To elect three Class I Directors for a three-year term expiring at the 2017 Annual Meeting; to ratify the selection by the Audit Committee of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2014; and to transact such other business as may properly come before the meeting or any adjournment thereof.

Tengion, Inc. Auditor Raises 'Going Concern' Doubt

Tengion, Inc. filed its 10-K on Mar 26, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNGN:US $0.16 USD -0.019

TNGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TENGION INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at